3EO Health Announces the First Point of Care Molecular Test Under $15
28 March 2024 - 9:00PM
Business Wire
- 3EO becomes the first point-of-care molecular technology to be
retail priced below $15 per test.
- 3EO adds a breakthrough business model enabling more physician
practices to upgrade technology from antigen to molecular without
the need for expensive and complex equipment, high-cost
consumables, or long-term contracts.
3EO Health, a “Point of Life” diagnostics company focused on the
development of high-performing low-cost molecular diagnostics, is
excited to announce the next step in their quest to make molecular
testing affordable. Today, the company has published a new market
price of $14.95 per test.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240327647032/en/
3EO high efficiency molecular 3TR
technology enables testing to be executed in multiple settings and
locations. 3EO's sample-to-test workflow eliminates the need for
mixing, pipetting, or technique dependent manual steps. With a cost
per test up to 70% lower than existing technologies, 3EO is seeking
to create access to molecular technology for more physicians and
consumers by providing molecular POC tests under $15. (Graphic:
Business Wire)
3EO’s proprietary 3TR technology was developed to enable
molecular performance at never-before-seen price points across a
number of clinical domains to include respiratory and sexually
transmitted infections. 3EO Health received EUA authorization for
its COVID-19 test utilizing 3TR technology in Q4 of 2023. With the
help of its U.S. suppliers and supply chain partners, 3EO is now
excited to be the first to offer point-of-care molecular testing
for under $15 per test.
“Constituents in U.S. healthcare are constantly feeling the
tension between cost and quality,” said Jeremy Schubert M.B.A,
M.P.H., Chief Executive Officer of 3EO Health. “Although molecular
technologies are more sensitive, antigen testing still dominates
the point of care market. Despite the perfusion of new
technologies, none have sufficiently reduced the cost or complexity
to enable clinicians to overcome this tension and make the move to
molecular. We are excited to be the first to simultaneously remove
both barriers.”
At $14.95 per test, 3EO costs up to 70% less than existing
technologies. 3EO is currently running programs with key
distributor partners for instrument acquisition and on-going
utilization that lower costs even further. Physicians should check
with one of 3EO’s authorized distributors for details.
For more information about 3EO Health and its 3TR Technology,
please visit 3EOhealth.com.
About 3EO
3EO Health Inc. is a “Point of Life” diagnostic company
leveraging novel technology to exponentially lower cost and expand
clinical and community access to high impact diagnostic tools. Our
passion is to create a world where every person is empowered to
optimize health - for their patients, communities, family, and
self. We seek to ensure physicians and consumers have equitable
access to the best technology that is both affordable and easy to
use. We enable people to thrive by extending the four walls of the
health system into the community, work, and home. Our mantra is “…
the right information, in the right place, at the right time,
enabling the right action, right now.” For more information visit
3EOhealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240327647032/en/
Melyssa St. Michael connect@3EOhealth.com 1 (844) LETS 3EO